KEPENEKLİ KADAYİFCİ, EDA2023-08-222023-08-222022-10-01Aykac K., Ozturk K., Demir O. O., Gumus D. D., Aslan S., Cem E., Celebi M. Y., Karabacak M. D., Alkan G., Aksoy F. D., et al., "Frequency and safety of COVID-19 vaccination in children with multisystem inflammatory syndrome: a telephonic interview-based analysis.", World journal of pediatrics : WJP, cilt.18, ss.700-705, 20221708-8569https://avesis.marmara.edu.tr/api/publication/7625688b-b0dd-436a-b2e6-34fa8536bd0b/filehttps://hdl.handle.net/11424/292765Coronavirus disease 2019 (COVID-19) vaccines are currently approved or authorized to prevent serious outcomes, such as severe disease, hospitalization, and death. The Pfizer- BioNTech vaccine is recommended for everyone aged five and older in the United States (US) to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1, 2]. However, it is unclear whether children with a history of multisystem, inflammatory syndrome in children (MIS-C) may be at risk for a MIS-like response following COVID-19 vaccination or SARS-CoV-2 reinfection [2]. Therefore, physicians remain uncertain about vaccinating children with a history of MIS-C. This study investigates the occurrence of severe, systemic side effects of COVID-19 vaccines and the recurrence of the MIS-C symptoms in children with a history of MIS-C to overcome vaccine hesitancy. We recruited children with a history of MIS-C diagnosed between April 2020 and December 2021 in seven hospitals in different regions of Turkey. Our study included three groups of children: (1) those with a history of MIS-C who met the US Center for Disease Control (CDC) or World Health Organization definitions for MIS-C [3, 4]; (2) those with a history of severe/critical COVID-19 [5]; (3) and those visiting hospitals for another reason and had no history of severe/ critical COVID-19 or MIS-C (controls). Children were called by phone and were asked to complete a questionnaire. We checked their vaccination status in the mobile application developed by the Republic of Turkey Ministry of Health to inform and guide citizens about COVID-19. Turkey authorized the Pfizer-BioNTech (mRNA) and Sinovac (inactivated virus) vaccines only for children aged 12 years or older. We developed a questionnaire including questions adopted from previous studies and new questions related to vaccine side effects reported by the CDC [6, 7]. Children with a MIS-C and severe/critical COVID-19 diagnosis and children without a MIS-C or severe/critical COVID-19 history were called by phone and were asked a standard set of questions that included their age, gender, and COVID-19 vaccination status. If the child had received a COVID-19 vaccination, we asked about the date of vaccination, the brand of the vaccine given, doses, side effects experienced (including their date and duration), polyclinic visit, and hospitalization. Children were asked about local and systemic reactions. Parents were asked questions about factors affecting their vaccination decision, including infection or reinfection anxiety in their family, information disseminated via social media, and advice from schools, friends, doctors, and the healthcare ministry.enginfo:eu-repo/semantics/openAccessPEDİATRİKlinik TıpKlinik Tıp (MED)PEDIATRICSCLINICAL MEDICINEClinical Medicine (MED)article1870070510.1007/s12519-022-00604-7